Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Company Overview

Allarity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing personalized cancer treatments. The company uses its Drug Response Predictor (DRP) technology to analyze tumor biology and identify patients who may be more likely to respond to specific therapies.

Allarity’s development programs have included dovitinib, an oral multikinase inhibitor investigated for use in advanced cancers, as well as other oncology candidates and drug-specific DRP companion diagnostics. The company’s approach is intended to support patient selection and improve the efficiency of clinical development by matching treatments with patients whose tumors are predicted to be sensitive to them.

The business has roots in Denmark and the United States. It was previously known as Oncology Venture A/S before adopting the Allarity Therapeutics name, reflecting its emphasis on precision oncology and its proprietary response-prediction platform. Its programs remain focused on the development of targeted therapies and diagnostic tools for cancer care.

Key Stats

• Today's Range: $1.11 to $1.22
• 50-Day Range: $1.11 to $1.43
• 52-Week Range: $0.77 to $1.84
• Volume: 185,434 shs
• Average Volume: 95,152 shs
• Market Capitalization: $19.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.25
• Consensus Rating: Hold

Allarity Therapeutics Stock Analysis - MarketRank™

Allarity Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 763rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Allarity Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Allarity Therapeutics has a consensus price target of $10.25, representing about 747.1% upside from its current price of $1.21.

Amount of Analyst Coverage

Allarity Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Allarity Therapeutics are expected to decrease in the coming year, from ($0.92) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allarity Therapeutics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allarity Therapeutics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Allarity Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.75% of the float of Allarity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allarity Therapeutics has a short interest ratio ("days to cover") of 1.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allarity Therapeutics has recently increased by 12.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allarity Therapeutics does not currently pay a dividend.

Dividend Growth

Allarity Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Allarity Therapeutics this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for ALLR on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.16% of the stock of Allarity Therapeutics is held by insiders.

Percentage Held by Institutions

11.53% of the stock of Allarity Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALLR
• CIK: 1860657
• Web: www.allarity.com
• Phone: 401-426-4664
• Fax: N/A
• Employees: 8
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Allarity Therapeutics: $10.25
• High Price Target: $10.25
• Low Price Target: $10.25
• Potential Upside/Downside: +747.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.23 million
• Net Margins: N/A
• Pretax Margin: -3,575.07%
• Return on Equity: -152.77%
• Return on Assets: -46.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.11
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $320 thousand
• Price / Sales: 60.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 1.98

Miscellaneous

• Outstanding Shares: 15,910,000
• Free Float: 15,886,000
• Market Cap: $19.25 million
• Optionable: Not Optionable
• Beta: 0.56